Viska Bio
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Oncology
Viska Bio is developing targeted extracellular oxidative therapies to convert “cold” tumors into “hot” tumors and enhance immunotherapy. Its proprietary nanobody–enzyme fusion platform combines a VHH domain with a modified xanthine oxidase to generate superoxide directly in the tumor microenvironment, with a modular design enabling flexible targeting. The lead program focuses on solid tumors including GBM, CRC, and NSCLC, with expansion into hematologic and potential non-oncology indications.
Program Summary:
VISK-103 is a first-in-class nanobody–enzyme fusion protein designed to generate reactive oxygen species within tumors. Proof-of-concept studies demonstrate EGFR-targeted binding, in vitro tumor cell killing, strong in vivo antitumor activity, and treatment-associated immune activation.
Company HQ City:
Cambridge
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2021
CEO
Eric Fossel, PhD.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}